Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6721 to 6735 of 8223 results

  1. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    25 January 2021

  2. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    21 March 2018

  3. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    3 April 2013

  4. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Published
    2 July 2015

  5. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    23 July 2015

  6. Neonatal specialist care (QS4)

    This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.

    Quality standard
    Published
    7 October 2010

  7. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Technology appraisal guidance
    Published
    26 June 2001

  8. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Evidence summary
    Published
    4 January 2013

  9. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  10. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  11. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Technology appraisal guidance
    Published
    12 July 2023

  12. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1054.

    Technology appraisal guidance
    Published
    16 November 2022

  13. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Technology appraisal guidance
    Published
    22 September 2004

  14. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Technology appraisal guidance
    Published
    16 December 2021

  15. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Technology appraisal guidance
    Published
    19 January 2022